BI 764532 Earns FDA FTD in Large Cell Lung Neuroendocrine Carcinoma
Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.
Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers
Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.
Multidisciplinary Care and New Treatment Options in CRC
New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.
Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma
Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.
FDA OKs Nirogacestat for Treatment of Desmoid Tumors
Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.
2 Clarke Drive Cranbury, NJ 08512